Andrew Bowser is a medical writer based in Brooklyn, New York.
Managing hedgehog therapies for basal cell carcinoma
February 19th 2018While the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week.
Spironolactone for hormonal acne
February 17th 2018Female patients with hormonal acne that typically flares before or after menstrual cycles may be ideal candidates for spironolactone, said Emmy M. Graber, M.D., president of the Dermatology Institute of Boston who spoke at AAD 2018 in San Diego this week.
Skin lupus can progress more rapidly than previously thought
February 16th 2018Systemic disease among patients with discoid lupus erythematosus, a chronic form of cutaneous lupus, can develop within one to two years of initial diagnosis, says Joseph F. Merola, M.D., reporting at the American Academy of Dermatology annual meeting in San Diego.
Higher Dosing 'Difficult to Straddle'
August 1st 2003Chicago - Escalating doses of an antibody to CTLA-4 in conjunction with a peptide vaccine showed the induction of antigen-specific immune responses and potential evidence of autoimmunity in patients with stage III/IV resected melanoma, according to Jeffrey M. Weber, M.D., Ph.D.
Psychology of psoriasis keys compliance
January 1st 2003New York - For treatment of localized psoriasis, breaking down the barriers to compliance can begin with something as simple as the human touch, according to Steven R. Feldman, M.D., Ph.D., director, Psoriasis Treatment Center, Wake Forest University School of Medicine, Winston-Salem, N.C.